Cereno Scientific AB (OSTO:CRNO B) Interest Expense : kr-31.96 Mil (TTM As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Cereno Scientific AB Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cereno Scientific AB's interest expense for the three months ended in Mar. 2025 was kr -7.47 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2025 was kr-31.96 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cereno Scientific AB's Operating Income for the three months ended in Mar. 2025 was kr -17.54 Mil. Cereno Scientific AB's Interest Expense for the three months ended in Mar. 2025 was kr -7.47 Mil. Cereno Scientific AB did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cereno Scientific AB Interest Expense Historical Data

The historical data trend for Cereno Scientific AB's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cereno Scientific AB Interest Expense Chart

Cereno Scientific AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Interest Expense

Get a 7-Day Free Trial

-0.27

-1.25

-0.46

-5.30

-26.09

Cereno Scientific AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Interest Expense	Get a 7-Day Free Trial															-1.60	-1.61	-7.46	-15.41	-7.47

Cereno Scientific AB Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-31.96 Mil.

Cereno Scientific AB (OSTO:CRNO B) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Cereno Scientific AB's Interest Expense for the three months ended in Mar. 2025 was kr-7.47 Mil. Its Operating Income for the three months ended in Mar. 2025 was kr-17.54 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2025 was kr180.40 Mil.

Cereno Scientific AB's Interest Coverage for the quarter that ended in Mar. 2025 is calculated as

Cereno Scientific AB did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Cereno Scientific AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cereno Scientific AB (OSTO:CRNO B) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

4A1:Germany

Address

BioVentureHub, Pepparedsleden 1, Molndal, SWE, 431 83

Website

https://www.cerenoscientific.se

Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Cereno Scientific AB Headlines

No Headlines